Tirzepatide is a medication that belongs to a class of drugs known as GLP-1 receptor agonists. It is used for the treatment of type 2 diabetes and weight loss.
In addition to its glucose-lowering effects, tirzepatide has been associated with significant weight loss in clinical
trials. This can be particularly beneficial for individuals with type 2 diabetes, as weight management
is a crucial aspect of overall diabetes care. Like other newer diabetes medications, tirzepatide has
undergone cardiovascular outcomes trials. These trials assess the impact of the medication on
cardiovascular events, providing valuable information on the safety and potential cardiovascular
benefits of the drug.
Starting at $450/vial Prices include prescription medication, tele-health visit with a practitioner, supplies and delivery.
What Is The Difference Between Tirzepatide and Semaglutide?
Semaglutide and tirzepatide are both in the class of drugs known as incretin mimetics and work similarly but have some differences in mechanism and dosing. Both drugs are FDA approved in various brand names as treatments for type 2 diabetes and long-term weight loss.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and mimics the natural GLP-1 hormone in our bodies. It binds to the GLP-1 receptor to exert its effect.
Tirzepatide is a dual-acting glucose-dependent insulinotropic polypeptide (GIP) and also glucagon-like peptide-1 (GLP-1) receptor agonist and binds to both GIP and GLP-1 receptors. Like GLP-1, GIP is also a natural incretin hormone and may increase the action of tirzepatide.
